However, TLR7 and TLR8 selective agonists or antagonists, inducing antiviral IFN response and/or controlling inflammation, deserve consideration and have entered phase II clinical trials as interesting therapeutic options to control the different manifestations of COVID-19 (ClinicalTrials.gov NCT04448756). This evidence concerns the gene IFNA1 and COVID-19.